WuXi PharmaTech Lays Off One-fifth Of U.S. Workforce Months After Acquiring American Biologics Firm AppTec
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Less than one year after acquiring the U.S.-based biologics outfit AppTec Laboratory Services in a $160-million deal, WuXi PharmaTech's senior management is preparing to lay off one-fifth of AppTec's 500 employees
You may also be interested in...
Hit By U.S. Economic Tremors, Collapse In Biologics Business, WuXi PharmaTech Posts Massive Loss For 2008, American Unit AppTec Deeply Devalued
BEIJING - Battered in succession by the unstable U.S. economy, faltering biologics customers and mounting losses by American subsidiary AppTec Laboratory Services, WuXi PharmTech reported a net loss of more than $60 million for 2008
Hit By U.S. Economic Tremors, Collapse In Biologics Business, WuXi PharmaTech Posts Massive Loss For 2008, American Unit AppTec Deeply Devalued
BEIJING - Battered in succession by the unstable U.S. economy, faltering biologics customers and mounting losses by American subsidiary AppTec Laboratory Services, WuXi PharmTech reported a net loss of more than $60 million for 2008
China’s WuXi Pharma Tech Shakes Up Its Board After Tumultuous Year
The West's financial morass could ultimately prod the world's pharmaceutical giants to outsource more research and development to lower-cost China, and to WuXi PharmaTech, CEO says.